

### Remarks

The specification amendments correct errors and they introduce no new matter.

5 New claims 38-48 replace original claims 30-37 and respond to the restriction the Office imposed. Exemplary written description support for the new claims is described below. Additional written description support is elsewhere in the disclosure. The new claims add no new matter.

Claim	Support
10 38	original claims 1 and 30
39	graft versus host disease - specification paragraphs 525 (page 215) and 993 (page 382)
40-42	chemical structures - original claim 1 structures
15 43	R <sup>4</sup> substituents - oxime (=NOH), =NO-optionally substituted alkyl - original claim 1 and paragraph 268 (page 78)
43	R <sup>4</sup> substituent -NH-optionally substituted alkyl - paragraph 254 (page 72)
44-45	3 $\beta$ -hydroxy-5-androstene-17 $\beta$ -methylamine is group 3 (paragraph 300, page 108) compound 1.1.5.4 (page 91, line 23) other compounds are group 3 compounds (group 3 compound 1.1.5.7 is 3 $\beta$ -hydroxy-5-androstene-17 $\beta$ -ethylamine) or are based on original claim 1
20 46	R <sup>10</sup> at the 9-position - paragraphs 812 and 813 (page 333)
47	R <sup>10B</sup> , R <sup>10C</sup> or R <sup>10E</sup> - paragraphs 822, 823 and 825 (page 334)
44, 48	R <sup>9</sup> moieties - paragraphs 323 and 325 (pages 117 and 119)
25	

### Restriction requirement

The Office required applicants to elect a single disclosed invention and a single disclosed compound species for examination. Applicants hereby elect the group IV invention, graft rejection. New claims 38-48 recite treatment of graft rejection and new claims 39-48 specifically recite treatment of graft versus host disease. Applicants also hereby elect for examination the compound 3 $\beta$ -hydroxy-5-androstene-17 $\beta$ -methylamine, which is compound 1.1.5.4 as described at paragraphs 296 and 300 (pages 90 and 108). New claims 38-45 read on this elected compound. Applicants believe that these elections fully respond to the restriction requirement.

Copending applications

The Office's attention is directed to commonly owned copending U.S.  
patent application serial Nos. 09/675,323, 10/651,515, 10/526,321, 10/728,400,  
10/319,356, 10/329,065, 10/602,330, 10/606,524, 10/607,035, 10/607,415,  
5 10/741,929, 10/876,957, 10/890,490, 10/949,694, 10/949,782, 10/877,911,  
10/087,929 and 11/241,678.

Applicants request examination on the merits.

10

Respectfully submitted,

Dated: May 17, 2006

15



Daryl D. Muenchau, Reg. No. 36,616  
Hollis-Eden Pharmaceuticals, Inc.  
9333 Genesee Avenue, Suite 200  
San Diego, CA 92121  
P: 858-320-2569  
F: 858-558-6470

20